Back to Search
Start Over
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.
- Source :
- Nature Reviews Cancer; Nov2011, Vol. 11 Issue 11, p805-812, 8p
- Publication Year :
- 2011
-
Abstract
- The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit. [ABSTRACT FROM AUTHOR]
- Subjects :
- IMMUNOTHERAPY
PROSTATE cancer treatment
MELANOMA treatment
IMMUNE response
TUMOR markers
THERAPEUTIC use of monoclonal antibodies
PROSTATE tumors treatment
THERAPEUTIC use of antineoplastic agents
RESEARCH
CLINICAL trials
MELANOMA
RESEARCH methodology
MONOCLONAL antibodies
ANTINEOPLASTIC agents
PROGNOSIS
EVALUATION research
MEDICAL cooperation
SKIN tumors
COMPARATIVE studies
RESEARCH funding
TISSUE extracts
PROSTATE tumors
Subjects
Details
- Language :
- English
- ISSN :
- 1474175X
- Volume :
- 11
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Nature Reviews Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 66748164
- Full Text :
- https://doi.org/10.1038/nrc3153